The European Directorate for the Quality of Medicines has established bilateral confidentiality agreements with the U.S. FDA and the Australian Therapeutic Goods Administration to share information regarding inspections of active pharmaceutical ingredients (API) and excipients manufacturers. The three organizations are involved in a pilot project to rationalize international good manufacturing practices (GMP) inspections. Release